Tulmimetostat
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Tulmimetostat, covering 2026-01-27 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) [Phase 1, Phase 2]